PL371313A1 - Modyfikowany polipeptyd - Google Patents

Modyfikowany polipeptyd

Info

Publication number
PL371313A1
PL371313A1 PL02371313A PL37131302A PL371313A1 PL 371313 A1 PL371313 A1 PL 371313A1 PL 02371313 A PL02371313 A PL 02371313A PL 37131302 A PL37131302 A PL 37131302A PL 371313 A1 PL371313 A1 PL 371313A1
Authority
PL
Poland
Prior art keywords
growth hormone
modified polypeptide
modified
binding domain
receptor
Prior art date
Application number
PL02371313A
Other languages
English (en)
Other versions
PL210714B1 (pl
Inventor
Richard Ross
Jon Sayers
Peter Artymiuk
Original Assignee
Asterion Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Limited filed Critical Asterion Limited
Publication of PL371313A1 publication Critical patent/PL371313A1/pl
Publication of PL210714B1 publication Critical patent/PL210714B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
PL371313A 2001-12-14 2002-12-06 Polipeptyd fuzyjny hormonu wzrostu, jego zastosowania medyczne, sposób wytwarzania, zawierająca go kompozycja farmaceutyczna oraz cząsteczka kwasu nukleinowego, wektor i transformowana lub transfekowana komórka PL210714B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0130052A GB2384001B (en) 2001-12-14 2001-12-14 Chimeric growth hormone-growth hormone receptor proteins

Publications (2)

Publication Number Publication Date
PL371313A1 true PL371313A1 (pl) 2005-06-13
PL210714B1 PL210714B1 (pl) 2012-02-29

Family

ID=9927705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371313A PL210714B1 (pl) 2001-12-14 2002-12-06 Polipeptyd fuzyjny hormonu wzrostu, jego zastosowania medyczne, sposób wytwarzania, zawierająca go kompozycja farmaceutyczna oraz cząsteczka kwasu nukleinowego, wektor i transformowana lub transfekowana komórka

Country Status (19)

Country Link
US (2) US7524649B2 (pl)
EP (2) EP1456385B1 (pl)
JP (2) JP5248734B2 (pl)
KR (3) KR100848802B1 (pl)
CN (2) CN100558899C (pl)
AT (1) ATE541935T1 (pl)
AU (1) AU2002366325B2 (pl)
CA (1) CA2468439A1 (pl)
ES (1) ES2378424T3 (pl)
GB (2) GB2384001B (pl)
HU (1) HUP0402496A3 (pl)
IL (3) IL162433A0 (pl)
MX (1) MXPA04005675A (pl)
NZ (1) NZ533550A (pl)
PL (1) PL210714B1 (pl)
RU (2) RU2346047C2 (pl)
SG (1) SG160205A1 (pl)
WO (1) WO2003070765A2 (pl)
ZA (2) ZA200404488B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447632C (en) * 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
MX2007001180A (es) * 2004-07-26 2007-04-13 Asterion Ltd Enlazantes.
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
GB0618082D0 (en) * 2006-09-14 2006-10-25 Asterion Ltd Growth factor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
WO2009077731A2 (en) * 2007-12-19 2009-06-25 Asterion Limited Prolactin fusion proteins
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
JP5412323B2 (ja) 2010-02-26 2014-02-12 日東電工株式会社 貼付製剤
GB201104285D0 (en) 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
EP2606908A1 (en) 2011-12-19 2013-06-26 Ipsen Pharma S.A.S. Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
AU2013214698B2 (en) * 2012-02-03 2017-02-16 Antisense Therapeutics Ltd Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
JP2016511275A (ja) * 2013-03-11 2016-04-14 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
WO2020014307A1 (en) * 2018-07-11 2020-01-16 Ohio University Peptide-based inhibitors of growth hormone action and methods of the thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
WO1992010576A1 (en) * 1990-12-13 1992-06-25 The Upjohn Company Fusion polypeptides
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
IT1251895B (it) * 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE69712124T2 (de) * 1996-02-13 2002-12-12 Jcr Pharmaceutical Co., Ltd. Hormones de croissance humaines mutantes et leur utilisation
ATE199570T1 (de) 1996-08-16 2001-03-15 Medical Res Council Selbst-replizierende episomale expressionsvektoren, welche gewebespezifische expression vermitteln
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2447632C (en) * 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins

Also Published As

Publication number Publication date
GB0130052D0 (en) 2002-02-06
IL162433A0 (en) 2005-11-20
JP2010043100A (ja) 2010-02-25
CN1604965A (zh) 2005-04-06
US20050123558A1 (en) 2005-06-09
IL162433A (en) 2011-09-27
AU2002366325A1 (en) 2003-09-09
WO2003070765A2 (en) 2003-08-28
EP1456385A2 (en) 2004-09-15
KR100879553B1 (ko) 2009-01-22
RU2008118104A (ru) 2009-11-20
GB0320479D0 (en) 2003-10-01
GB2384001A (en) 2003-07-16
GB2389115A (en) 2003-12-03
US7524649B2 (en) 2009-04-28
RU2346047C2 (ru) 2009-02-10
KR20040083470A (ko) 2004-10-02
HUP0402496A3 (en) 2012-03-28
ZA200404488B (en) 2006-03-29
SG160205A1 (en) 2010-04-29
CN100558899C (zh) 2009-11-11
CN101638437A (zh) 2010-02-03
IL200659A0 (en) 2010-05-17
JP5248734B2 (ja) 2013-07-31
KR100848802B1 (ko) 2008-07-28
CA2468439A1 (en) 2003-08-28
EP2365085A1 (en) 2011-09-14
KR20070108254A (ko) 2007-11-08
EP1456385B1 (en) 2012-01-18
HUP0402496A2 (hu) 2005-03-29
US20090239801A1 (en) 2009-09-24
ATE541935T1 (de) 2012-02-15
RU2004117777A (ru) 2005-05-10
NZ533550A (en) 2006-02-24
AU2002366325B2 (en) 2008-04-24
WO2003070765A3 (en) 2003-11-27
ES2378424T3 (es) 2012-04-12
GB2389115B (en) 2005-03-16
PL210714B1 (pl) 2012-02-29
GB2384001B (en) 2004-02-04
ZA200600149B (en) 2006-10-25
KR20060106862A (ko) 2006-10-12
MXPA04005675A (es) 2005-04-19
JP2005525106A (ja) 2005-08-25
HK1070669A1 (en) 2005-06-24

Similar Documents

Publication Publication Date Title
IL200659A0 (en) Modified polypeptide
IL222149B (en) A protein comprising a modified version of the fc region of a human antibody with increased binding affinity to fcrn
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
IL229857A0 (en) 1rp7b mature polypeptide binding antibody
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
WO1998038212A3 (en) Chimeric polypeptides containing chemokine domains
PT2241575E (pt) Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
IL161016A (en) Polypeptides capable of ang-2 binding
IL146451A0 (en) C-terminal protein tagging
IL181005A0 (en) Polypeptide comprising binding domains
AU2002250049A8 (en) Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
AU2002357427A8 (en) Peptide or protein containing a c'-d loop of the cd28 receptor family
MXPA00003885A (es) Quimiocinas con modificiaciones de la terminacion amino.
AU3087599A (en) Human appetite control by glucagon-like peptide receptor binding compounds
MXPA02002767A (es) Usos terapeuticos del polipeptido m3.
AU1510801A (en) A novel polypeptide, a human s100 calcium binding protein 21 and the polynucleotide encoding the polypeptide
AU2002214914A1 (en) A novel polypeptide- t1/st2 receptor binding protein 10.23 and the polynucleotide encoding said polypeptide
AU2001293639A1 (en) A novel polypeptide-human tnfr/ngfr protein 15 that contains cytochrome c structural domain and the polynucleotide encoding said polypeptide
EP0572122A3 (en) C-terminal modified osteogenic growth polypeptides.
GB9924960D0 (en) Novel polypeptide
AU4405201A (en) A novel polypeptide-human protein 17 containing chromo domain and the polynucleotide encoding said polypeptide
AU2001295401A1 (en) A novel polypeptide-homo tnfr/ngfr protein 9.02 containing cytochrome c structural domain and polynucleotide encoding said polypeptide
AU8953101A (en) A novel peptide---human tnfr/ngfr protein including cytochrome c domain and the polynucleotide coding this novel peptide
AU7898700A (en) A novel polypeptide-rna binding protein 33 and polynucleotide encoding said polypeptide

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20121206